A carregar...
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3493328/ https://ncbi.nlm.nih.gov/pubmed/22681723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-5-283 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|